Skip to main navigation
menu

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Drug Development Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Extras Menu

  • Media resources
  • Contact us

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Drug Development Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Investor Relations

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events
  • SEC Filings
  • Corporate Governance
  • Investor Presentations
  • Investor FAQs
  • Email Alerts
Investor Contact
For investor related questions, please email
investors@aclaristx.com

Investor Overview

Stock quote
  
 
VOLUME:
View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases
November 13, 2023
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
November 6, 2023
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
October 3, 2023
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
View all »
Events
Nov 13, 2023
8:00 AM EST
Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results
Sep 26, 2023
10:30 AM EDT
Aclaris Therapeutics at 2023 Cantor Global Healthcare Conference
Jun 14, 2023
4:40 PM PDT
Aclaris Therapeutics at 44th Annual Goldman Sachs Healthcare Conference
View all »
Feature Presentation
thumbnail
Aclaris Therapeutics Presents ATI-450 Phase 2b Rheumatoid Arthritis Data

Aclaris - Footer Menu

  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Fraudulent Activity Notice
© 2023 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.